![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV's EPIT(TM) Disease Modifying Effect
June 10, 2014 12:05 ET
|
DBV Technologies
BAGNEUX, France, June 10, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, presented today...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin(R) at the French Congress of Allergy
April 16, 2014 01:37 ET
|
DBV Technologies
Dr. Thierry Bourrier and Pr. Christophe Dupont present abstract showing that a peanut-allergic child from the ARACHILD study had a sustained desensitization even after one year off treatment...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies : DBV Technologies Announces Topline Financial Results for First Three Months 2014
April 15, 2014 01:33 ET
|
DBV Technologies
BAGNEUX, France, April 15, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new reference in the treatment of allergy, announced today its...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
Presentation and Publication of Research at AAAAI Demonstrates EPIT(TM)'s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect
March 04, 2014 12:05 ET
|
DBV Technologies
BAGNEUX, France, March 4, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, today announced that...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies' Viaskin(R) Peanut in the treatment of peanut allergy
October 24, 2013 02:14 ET
|
DBV Technologies
Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV' team
CoFAR6 study will help to better...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin(R) for Refractory Hemophilia A Disease
October 22, 2013 12:33 ET
|
DBV Technologies
BAGNEUX, France, Oct. 22, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext:DBV) (ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, announced today that it...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin(R) Peanut
October 15, 2013 02:49 ET
|
DBV Technologies
BAGNEUX, France, Oct. 15, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext:DBV) (ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its...